Trulicity ® (dulaglutid) injektion

För fullständig produktresumé för Trulicity® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Trulicity® (dulaglutid): Byte från annan GLP-1 receptor agonist

Inga studier har gjorts på effekterna av att byta från en annan GLP-1 RA till dulaglutide.

Detailed Information

Dulaglutide is a GLP-1 RA indicated for once weekly dosing as an adjunct to diet and exercise for the treatment of adults with unsufficiently controlled T2DM.1 

No studies have been performed regarding switching to dulaglutide from another GLP-1 RA.

Physicians should follow their clinical judgment, taking into account the patient’s glycemic control, when deciding how to switch from one GLP-1 RA to another one. 

When switching a patient from another GLP-1 RA to dulaglutide, the prescribing information of the applicable GLP-1 RA and pharmacokinetic profile should be considered including

  • onset of action

  • duration of action

  • half-life

  • time to steady state, and 

  • missing dosing information.

Improvement in glycemic control with dulaglutide after the first administration is sustained throughout the once weekly dosing interval. The half-life of dulaglutide is approximately 5 days and steady-state concentrations of dulaglutide are achieved within 2 to 4 weeks.1

References

1. Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

GLP-1 RA = glucagon-like peptide-1 receptor agonist

T2DM = type 2 diabetes mellitus

Datum fӧr senaste ӧversyn 2018 M10 11


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss